

Item 5.07 Submission of Matters to a Vote of Security Holders.

The 2015 Annual Meeting of Stockholders of PharMerica Corporation (the “Company”) was held on June 19, 2015.

¹ The Company’s stockholders approved the election of the following nine directors for a term to expire at the Annual Meeting of Stockholders in 2016. The votes for each director were as follows:

| Name | For | Withheld Authority | Broker Non-Votes |
|--------------------------|------------|--------------------|------------------|
| Frank E. Collins, Esq. | 26,312,400 | 425,029 | 2,227,397 |
| W. Robert Dahl, Jr. | 26,541,693 | 195,736 | 2,227,397 |
| Marjorie W. Dorr | 26,545,191 | 192,238 | 2,227,397 |
| Thomas P. Gerrity, Ph.D. | 26,316,311 | 421,118 | 2,227,397 |
| Patrick G. LePore | 26,539,421 | 198,008 | 2,227,397 |
| Thomas P. Mac Mahon | 26,539,090 | 198,339 | 2,227,397 |
| Geoffrey G. Meyers | 26,318,584 | 418,845 | 2,227,397 |
| Robert A. Oakley, Ph.D. | 26,541,020 | 196,409 | 2,227,397 |
| Gregory S. Weishar | 25,539,361 | 198,068 | 2,227,397 |

² The Company’s stockholders voted upon the ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015. The votes on this proposal were as follows:

| For | Against | Abstained |
|------------|---------|-----------|
| 28,879,980 | 75,422 | 9,424 |

³ The Company’s stockholders voted upon and approved, by advisory vote, the compensation of the Company’s named executive officers. The votes on this proposal were as follows:

| For | Against | Abstained | Broker Non-Votes |
|------------|-----------|-----------|------------------|
| 24,801,009 | 1,703,482 | 232,938 | 2,227,397 |

⁴ The Company’s stockholders voted upon and approved and adopted the PharMerica Corporation 2015 Omnibus Incentive Plan. The votes on this proposal were as follows:

| For | Against | Abstained | Broker Non-Votes |
|------------|-----------|-----------|------------------|
| 23,399,246 | 3,221,514 | 116,669 | 2,227,397 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMERICA CORPORATION

Date: June 23, 2015 By: /s/ Thomas A. Caneris
Thomas A. Caneris
Senior Vice President, General Counsel, Chief
Compliance Officer, and Secretary
